Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

Table 1 Demographic data

Patient ID	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Gender	Female	Female	Male	Male	Male
Age	51	51	54	45	53
Weight	94	70	88	95	102
Initial vital signs (base)
RR breaths/min	22	28	42	36	28
PR beats/min	71	92	89	66	92
Sys BP, mmHg	141	103	124	139	138
Dias BP, mmHg	76	71	89	90	97
Temp > 37.3 (°C, baseline)	37	37.3	36.7	37.4	36.2
SO₂ (without oxygen mask)	87	70	79	80	89
Other
COVID type	Sev	Sev	Sev	Sev	Sev
Comorbidities	Fatty liver disease	HTN	Damaged lung	No	Diabetes
Interval between symptoms onset and admission (days)	6	10	11	13	4
Interval between symptoms onset and first cell injection (days)	10	14	13	17	7
Duration of hospitalization in ICU after cell injection	7	5	0	6	0
Conventional therapy	Hep/Dexa	Hep/Dexa	Hep/Dexa	Hep/Dexa	Hep/Dexa/Ataz
RT-PCR at admission	+	+	+	+	+

Sev severe, HTN hypertension, Hep heparin, Dexa dexamethasone, Ataz atazanavir, RT-PCR reverse transcription polymerase chain reaction

ISSN: 1757-6512